+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 10 Actively Recruiting clinical trials

O

Actively Recruiting

Researchers are studying the physical impact of Multiple Sclerosis MS from the patients perspective while providing continued access to the drug ocrelizumab. This extension study evaluates the safety and tolerability of ocrelizumab in patients previously enrolled in certain parent studies who no longer have local access to the treatment. The study is open-label and multicenter, sponsored by Hoffmann-La Roche. Participants will receive ocrelizumab at approved doses of either 600 mg via intravenous infusion or 920 mg via subcutaneous injection, following the schedule from their original parent study. Treatment will continue until the medication becomes locally available, an unacceptable safety concern arises, the participant dies, or withdraws consent. During the study, participants will be monitored for changes in physical function using patient-reported outcome measures over up to five years. Researchers will also track access to ocrelizumab, serious adverse events, adverse events leading to discontinuation, and adverse events of special interest. The study will last up to five years, with ongoing safety and tolerability assessments throughout the treatment period.

Age: 18Years +All GendersPhase 3
56 locations
O

Actively Recruiting

Researchers are evaluating the safety, efficacy, and tolerability of sodium zirconium cyclosilicate SZC in children under 18 years old with hyperkalaemia, a condition involving high potassium levels. This phase 3, open-label study involves about 140 participants across roughly 46 sites in Europe, North America, and other locations. It starts with two age cohorts 6 to under 12 years and 12 to under 18 years, with potential expansion to younger cohorts based on data review by an independent monitoring committee. Treatment includes three phases the Correction Phase CP, Maintenance Phase MP, and Long-Term Maintenance Phase LTMP. Participants in CP receive SZC orally three times daily for up to 3 days until potassium levels normalize, with doses adjusted by body weight equivalent to adult doses of 5 g, 10 g, or 15 g. Those achieving normal potassium enter the MP, receiving once-daily SZC for 28 days with dose adjustments to maintain levels. Participants may then continue into the LTMP, following a similar dose regimen with monthly visits. Throughout the study, participants undergo blood tests, ECG monitoring, urine analyses, and safety assessments to track potassium levels, aldosterone, electrolytes, and kidney function. Researchers measure effectiveness by the ability to achieve and maintain normal potassium levels and monitor safety and tolerability in all phases. The study duration is about 28 weeks, including treatment and a safety follow-up one week after the last dose.

Age: 0Years - 18YearsAll GendersPhase 3
70 locations
E

Actively Recruiting

Researchers are evaluating the diagnostic accuracy and operational features of the Bioneer Accupower Q-RFIA PCR kit used on the IRON qPCR system for detecting tuberculosis TB and resistance to key anti-TB drugs including isoniazid, rifampicin, fluoroquinolones, and aminoglycosides. This multicenter observational study aims to support global and national decisions by providing robust evidence on the validity of this rapid test, which integrates sample preparation and can deliver results within 30 minutes. The study compares the investigational assay with existing diagnostic tests and uses culture and molecular sequencing as reference standards. Participants suspected of pulmonary TB will provide sputum samples that will be tested with the Bioneer RFIA kit and comparator assays such as Xpert MTBRIF Ultra and Xpert MTBXDR. The study assesses both direct sputum samples and cultured isolates to compare diagnostic performance and resolve any discordant results. Additional tests include smear microscopy, culture on different media, phenotypic drug susceptibility testing, and whole genome sequencing for samples with discrepant resistance results. Retrospective specimens from biobanks may also be included for testing. During the study, participants provide sputum specimens which undergo multiple diagnostic tests at various laboratories following standardized procedures. Data on test results and resistance detection are recorded systematically. The primary outcomes include diagnostic accuracy for TB detection and drug resistance identification over 8 months. The study follows rigorous quality control, safety, and ethical standards to ensure reliable results and participant safety throughout the study period ending in mid-2027.

Age: 18Years +All Genders
5 locations
I

Actively Recruiting

Healthy Volunteer

Researchers are investigating the outcomes for mothers diagnosed with cancer during pregnancy, focusing on overall survival and the long-term development of children exposed to cancer or cancer treatments before birth. The study aims to understand how prenatal exposure to therapies like chemotherapy, radiation, or targeted treatments may affect childrens neurological and heart health as they grow. The study includes several parts initially, it registers and tracks maternal and neonatal health during pregnancy and delivery, including collecting blood samples and tissue biopsies. Emotional needs of parents facing a cancer diagnosis are assessed through questionnaires. The second part follows children exposed in utero to cancer treatments with regular check-ups at various ages up to adulthood, including neurological and cardiological exams, and optional MRI sessions. Participants will undergo scheduled assessments including blood sample collection, placental biopsies, and questionnaires for parents. Children will have neurological and heart evaluations at set ages from 6 months through 18 years, with further cardiologic monitoring every five years into adulthood. The research team monitors overall survival in mothers and developmental outcomes in children, ensuring comprehensive long-term follow-up extending potentially into the fourth decade of life for offspring.

Age: 18Years +FEMALE
33 locations
W

Actively Recruiting

Researchers are evaluating the efficacy and safety of cariprazine in treating schizophrenia among adolescents aged 13 to 17 years. This international, multicenter study is designed as a randomized, double-blind, placebo-controlled trial to understand how cariprazine affects symptoms of schizophrenia in this younger population. Participants will be randomly assigned to receive either cariprazine capsules at doses of 1.5 mg or 4.5 mg once daily, or matching placebo capsules once daily. The treatment phase lasts for six weeks, during which participants take the assigned capsules orally every day. During the study, participants will be monitored regularly to assess changes in their schizophrenia symptoms using the Positive and Negative Syndrome Scale PANSS. Researchers will also evaluate safety and tolerability throughout the trial. The main measurement is the change in PANSS total score from the start to the end of the six-week period. The study is designed to last until December 2026.

Age: 13Years - 17YearsAll GendersPhase 3
57 locations
P

Actively Recruiting

Researchers are evaluating the effectiveness and safety of masitinib combined with riluzole compared to a placebo combined with riluzole for treating Amyotrophic Lateral Sclerosis ALS. This phase 3 study focuses on patients diagnosed with probable or definite ALS, aiming to understand how masitinib, a drug that targets cells involved in neuroinflammation, might slow disease progression and affect the nervous systems environment. Participants receive oral masitinib at 3.0 mgkgday twice daily, with dose increases to 4.5 mgkgday after 4 weeks, and for some, an additional increase to 6.0 mgkgday after another 4 weeks. Each dose increase includes safety monitoring. Masitinib is given alongside riluzole, a standard ALS treatment at 50 mg twice daily. The control group receives a matching placebo with riluzole. The study is randomized, double-blind, and includes two different masitinib dose escalation schedules. During the 48-week study period, participants undergo regular assessments including functional rating scales ALSFRS-R, quality of life questionnaires ALSAQ-40, survival and progression monitoring, lung function tests FVC, and muscle strength measurements HHD. Researchers measure changes in combined function and survival scores. Safety is closely monitored throughout, with follow-up extending up to 36 months for disease progression or death. Total participation includes baseline screening, treatment, and long-term observation.

Age: 18Years - 81YearsAll GendersPhase 3
56 locations
G

Actively Recruiting

This research aims to collect real-world data on patients with type 2 diabetes, hypertension, heart failure, and chronic kidney disease. It focuses on understanding patient characteristics, disease management, healthcare use, and outcomes across many countries. The study is an observational registry that includes patients seen in regular clinical practice worldwide. Participants are grouped based on their main condition or comorbidities, including type 2 diabetes, hypertension, chronic kidney disease, or heart failure. Data is collected both retrospectively and prospectively using a cloud-based electronic case report form accessible to investigators and a scientific committee. The registry is open to all physicians managing these conditions globally. Participants contribute information about their health status, treatments, and clinical measurements over time. Researchers gather demographic data, disease history, lab tests, imaging, medication use, healthcare visits, and outcomes such as hospitalizations and complications. The study measures many health indicators at baseline and averages over three years to understand care quality and disease progression. Participation can last until the study ends in 2030.

Age: 18Years +All Genders
76 locations
L

Actively Recruiting

Researchers are studying the long-term safety and effectiveness of pembrolizumab MK-3475 in participants with advanced tumors or blood cancers who were part of previous pembrolizumab-based studies. This extension study includes participants currently receiving treatment or in follow-up from parent trials. It consists of three phases the First Course Phase, Survival Follow-up Phase, and Second Course Phase, depending on the participants status at the end of their previous study. Participants may receive pembrolizumab alone or combined with standard of care treatments, lenvatinib, or other study drugs like olaparib and MK-4280, delivered mainly by intravenous infusion or oral capsules. Dosing schedules vary, including pembrolizumab administered every 3 or 6 weeks for up to 35 or 17 doses depending on the phase. Some participants may take lenvatinib orally daily, timed with pembrolizumab infusions, while others may receive investigational combination therapies or standard care treatments according to their parent studys protocol. During the study, participants will have regular infusions or oral dosing and be monitored over several years for overall survival and other outcomes like progression-free survival and adverse events. Researchers will assess safety and efficacy for up to approximately 10 years, with detailed tracking of side effects and treatment discontinuations. Study visits and assessments will be conducted to evaluate organ function, disease status, and any treatment-related effects throughout the study duration.

Age: 18Years +All GendersPhase 3
782 locations
S

Actively Recruiting

Researchers are studying the safety and tolerability of low motoneuron stimulation using high-frequency repetitive transcranial magnetic stimulation HF-rTMS in people with spinal muscular atrophy SMA. SMA is a condition where muscle weakness occurs due to nerve problems, and exercise may help prevent muscle loss. However, regular exercise can be difficult for people with SMA due to physical and psychological challenges. This trial explores whether HF-rTMS can mimic exercise effects on muscles, especially for those who cannot perform physical activities easily. Participants will receive HF-rTMS targeting the primary motor cortex of the limbs at a frequency above 5 Hz and intensity of 90-100% of their resting motor threshold. The treatment involves up to 10 sessions, each delivering up to 2400 stimuli. Additionally, cerebrospinal fluid will be collected via lumbar puncture before and after the treatment to measure specific proteins related to SMA. During the study, participants will undergo assessments of motor function using several scales and tests, including the Motor Function Measure Scale, the Revised Upper Limb Module, the Hammersmith Functional Motor Scale - Expanded, and the 6-Minute Walk Test. These will be performed before the first TMS session and shortly after the last session. The study evaluates changes in motor abilities and monitors safety and tolerability throughout the trial, which runs until January 2026.

Age: 12Years +All GendersPhase Not Applicable
1 location
C

Actively Recruiting

This clinical trial, known as the FLOTILLA study, provides continued access and safety follow-up for participants who were part of previous clinical trials involving encorafenib andor binimetinib. It is designed for individuals who are still benefiting from these study medicines, as determined by their study doctor. The study is conducted under a Master Protocol and includes multiple continuation sub-studies for participants from various earlier trials. Participants will receive the same study treatment as in their prior parent study, maintaining the same dose and frequency of encorafenib, binimetinib, or other related medicines such as vemurafenib, ribociclib, cetuximab, pembrolizumab, nivolumab, and chemotherapy drugs. Treatments are administered orally or intravenously according to the specific drug schedule. Treatment may continue for up to about five years while participants remain on therapy and benefit clinically. During the study, participants will be regularly monitored for safety, including tracking adverse events and serious adverse events that could lead to stopping the study drug. Researchers will assess these safety measures from the start of participation through approximately five years. The study aims to closely follow participants health and treatment tolerability throughout this extended period, with ongoing evaluations and follow-up visits.

Age: 18Years +All GendersPhase 4
77 locations